Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
Rhea-AI Summary
Zymeworks (Nasdaq: ZYME) announced full-time appointments of Dr. Adam Schayowitz as Executive VP & Head of R&D and Scott Platshon as Executive VP & Chief Business Officer, effective April 9, 2026.
Both report to CEO Kenneth Galbraith and will advance clinical programs, asset aggregation, and management of licensed assets including Ziihera and pasritamig. The company cited Phase 1 initiation for ZW251 and positive Phase 3 HERIZON-GEA-01 data for zanidatamab as momentum supporting its integrated R&D and partnership strategy.
AI-generated analysis. Not financial advice.
Positive
- Leadership appointments of seasoned R&D and business executives
- Phase 3 positive data for zanidatamab (HERIZON-GEA-01)
- Phase 1 initiation for investigational candidate ZW251
- Asset aggregation strategy to diversify revenue from licensed assets
Negative
- Dependence on partners to advance licensed programs (e.g., pasritamig via Johnson & Johnson)
- Executives sourced from a significant shareholder (EcoR1 Capital), which may raise governance scrutiny
News Market Reaction – ZYME
On the day this news was published, ZYME gained 2.40%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ZYME gained 2.73% while key biotech peers like DNTH (-1.14%), PGEN (-3.74%), NTLA (-1.7%) and RCUS (-0.22%) mostly traded lower, indicating a stock-specific reaction to the leadership appointments.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 01 | CFO appointment | Positive | +3.6% | New CFO with capital markets experience to support strategic execution. |
| Mar 30 | Regulatory designation | Positive | +0.1% | FDA Fast Track designation for ZW191 in platinum‑resistant ovarian cancer. |
| Mar 24 | Conference participation | Neutral | -1.8% | Planned participation in upcoming investor conferences and meetings. |
| Mar 18 | Clinical data plans | Positive | -2.5% | Multiple AACR presentations highlighting Ziihera clinical and mechanistic data. |
| Mar 17 | Pipeline data update | Positive | -2.5% | AACR presentations on ADC programs including novel RAS ADC platform. |
Recent positive corporate and clinical updates have often led to mixed price reactions, with leadership news skewing more positively and some scientific conference announcements seeing selling pressure.
Over the past month, ZYME has reported several strategic and clinical milestones. On Mar 2, filings detailed growing royalty streams and 2025 revenue of $106.0 million. Subsequent AACR-related data updates on Ziihera and ADC programs around Mar 17–18 saw negative price reactions despite constructive scientific content. More recently, Fast Track designation for ZW191 on Mar 30 and the CFO appointment on Apr 1 were followed by modest to strong gains. Today’s executive appointments continue the focus on leadership and execution across a growing royalty-backed pipeline.
Market Pulse Summary
This announcement reinforces ZYME’s emphasis on execution by elevating experienced leaders to Head of R&D and Chief Business Officer as of April 9, 2026. The appointments are framed against recent milestones such as ZW251 entering a Phase 1 study and pasritamig progressing into Phase 3 registration work. Investors may track how this team advances the royalty-backed asset portfolio, delivers on clinical timelines, and manages partnerships to support long-term value creation.
Key Terms
phase 1 medical
phase 3 medical
biotherapeutics medical
AI-generated analysis. Not financial advice.
• Adam Schayowitz, Ph.D., MBA appointed as Head of R&D
• Scott Platshon appointed as Chief Business Officer
VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the full-time appointments of Dr. Adam Schayowitz and Mr. Scott Platshon as of April 9, 2026, from their previously interim roles. Both Dr. Schayowitz and Mr. Platshon will report directly to Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.
“These appointments come at a pivotal time for Zymeworks as we enter a year focused on execution across our pipeline, partnerships, and broader corporate strategy,” said Galbraith. “Adam’s deep oncology and R&D expertise will accelerate our clinical development and unlock additional value, while Scott’s investment acumen and strategic vision will be instrumental in helping to expand our asset portfolio and drive long-term returns. Together with the recent appointment of Ms. Kristin Stafford as Chief Financial Officer, these leadership additions better position Zymeworks to execute on its strategy and deliver sustained value for patients and shareholders.”
Dr. Schayowitz has been appointed as Executive Vice President and Head of Research & Development. He will work closely with Zymeworks’ R&D and Business Development teams to advance the Company’s portfolio of product candidates, while supporting its strategy to integrate partnerships and collaborations into its wholly-owned R&D pipeline. With nearly two decades of experience in oncology drug development, Dr. Schayowitz will play a key role in advancing programs in areas of high unmet need and preparing additional product candidates for progression into clinical studies.
Mr. Platshon will serve as Executive Vice President and Chief Business Officer and continue to lead Zymeworks’ asset aggregation strategy while managing expected future cash flows from Ziihera® (zanidatamab-hrii) and other licensed healthcare assets, including pasritamig, which is being advanced into Phase 3 registration studies by Johnson & Johnson Innovative Medicine. In his full-time role as Chief Business Officer, he is responsible for executing Zymeworks’ strategy to build and actively manage a diversified portfolio of revenue-generating assets to help drive long-term shareholder value.
Dr. Schayowitz and Mr. Platshon both join the executive leadership team from EcoR1 Capital, a significant shareholder in Zymeworks.
Recent milestones, including the Phase 1 study initiation for ZW251 and expanding global approvals of zanidatamab, underscore Zymeworks’ continued momentum across its development pipeline and strategic partnerships. The Company remains focused on disciplined execution while advancing a differentiated strategy that integrates R&D innovation with strategic collaborations.
Building on this progress, Zymeworks is advancing a diversified portfolio of revenue-generating assets supported by its asset aggregation strategy. Positive Phase 3 HERIZON-GEA-01 data for zanidatamab further strengthens the Company’s position to drive long-term value through a balanced approach that combines internal pipeline advancement with active management and expansion of its royalty and licensed asset portfolio. This integrated model is designed to optimize future cash flows while supporting continued investment in innovative therapeutics.
About Zymeworks Inc.
Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. Zymeworks’ asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera® (zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the development of innovative medicines. Zymeworks engineered and developed Ziihera, a HER2-targeted bispecific antibody using the Zymeworks’ proprietary Azymetric™ technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Zymeworks’ complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Cautionary Note Regarding Forward-Looking Statements
This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to Zymeworks’ expectations regarding implementation of its strategic priorities and long-term strategy to maximize value creation; the expected contributions of personnel to Zymeworks’ clinical development, strategic goals and long-term shareholder value for patients and shareholders; the anticipated benefits of strategic partnerships; Zymeworks’ and its partners’ clinical development and advancement of product candidates; future regulatory filings and approvals; the commercial potential of technology platforms and product candidates; and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “on track”, “progress”, “preserve”, “intend”, “could”, “position” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; Zymeworks may not achieve milestones or receive additional payments or royalties under its collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory delays and uncertainty around recent policy developments, changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of global and regional geopolitical or public health developments on Zymeworks’ business, research and clinical development plans and timelines and results of operations; zanidatamab may not be successfully commercialized; Zymeworks’ business strategy related to anticipated and potential future milestones and royalty streams and existing and potential new partnerships may not be successfully implemented; Zymeworks’ evolution of its business strategy may not deliver meaningful shareholder returns; Zymeworks may be unsuccessful in actively managing and/or aggregating revenue-generating assets alongside its active R&D operations; ongoing and future clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; data providing early validation of our antibody drug conjugate platform and next generation pipeline programs may not be replicated in future studies; Zymeworks’ assumptions and estimates regarding its financial condition, future financial performance and estimated cash runway may be incorrect; inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under “Risk Factors” in Zymeworks’ quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedarplus.ca).
Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Vice President, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove
Vice President, Corporate Communications
(604) 678-1388
media@zymeworks.com
